linjc16/ctgov huggingface dataset:
Protecting the Corneal Endothelium During Cataract Surgery Using the Anterior Capsule

Study Overview
=================
Brief Summary
-----------------
Cataract surgery is one of the most frequently performed surgical procedures worldwide. Since the introduction of phacoemulsification to remove the cataractous lens, risk and complication rates of cataract surgery decreased significantly. The phacoemulsification technique utilizes a high-intensity ultrasound energy for the fragmentation and emulsification of the lens. One of the main complications during phacoemulsification, is damaging of the endothelium due to contact with lens fragments of the nucleus following turbulent flow of irrigating solution, resulting in corneal damage, inflammation of the endothelium and corneal edema. In this study we want to evaluate the effect of the anterior capsule, gained by capsular rhexis, as a corneal shield during phacoemulsification on the corneal endothelium.

Official Title
-----------------
Protecting the Corneal Endothelium During Cataract Surgery Using the Anterior Capsule: a Prospective Randomised Double-masked Study

Conditions
-----------------
Endothelial Cell Loss, Corneal

Intervention / Treatment
-----------------
* Procedure: Rhexis protection shield


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cataract Age 21 and older Written informed consent prior to surgery Moderate to severe nuclear or mixed cataract Exclusion Criteria: Corneal pathologies Pregnancy Patients with an increased surgical risk (i.e. patients with pseudoexfoliation syndrome, patients with the potential risk of intra-operative floppy iris syndrome)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Study group<br>rhexis protection shield | Procedure: Rhexis protection shield<br>* In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation<br>|
| No Intervention: Control group<br>regular surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelium cell loss | Comparison of the lost endothelium cells in both groups | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| central corneal thickness | Comparison of corneal thickness between both groups | 1 year |
Outcome of Women With Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
Squamous cell carcinoma (SCC) of the cervix has showed a marked decline in developed countries over the past 40 years, however, there has also been an increase in relative and absolute incidence of adenocarcinoma and adenosquamous carcinoma (AC) of the uterine cervix over the same period. Our understanding of the natural history and optimal management of AC is limited. It appears that AC and SCC of the cervix behave differently. They are different in epidemiology, prognostic factors, and patterns of failure after similar treatments. Available data suggest that they may also differ in their response to treatment. We postulate that new treatment strategies specifically tailored to AC should be explored. However, there is few data about outcome of cervical cancer in Taiwan. So we propose this proposal for retrospective analysis of clinicopathological parameters and outcomes in patients of cervical cancer, especially for cervical adenocarcinoma and adenosquamous carcinoma.

Conditions
-----------------
Cervical Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Time interval: from 1991 to date. Comprehensive surgical staging, debulking procedure, radiotherapy or chemotherapy. All female patients with cervical cancer who underwent treatment for cervical cancer at Far Eastern Memorial Hospital. All the patients diagnosed as cervical cancer, especially for women with adeno- and adenosquamous carcinoma. To review: Clinical data: including age at diagnosis, presenting symptoms, gravidity, parity, menstrual history, body mass index, history of diabetes, hypertension, personal history of cancer and staging. Pathologic information: deep stromal invasion, lymph-vascular space invasion, lymph node involvement, parametrium invasion, vaginal cut end and tumor size. Survival data: disease-free and overall survival. Radiation report, Chemotherapy treatment, operation, discharge and admission note. Exclusion Criteria: Not comprehensive staging/debulking procedure. Patients who died of postoperative complications within 30 days after surgery were excluded from the survival analysis. Female minors or disabled persons.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases with cervical cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcome of women with cervical cancer |  | 20 years |
Helping Hands: Promoting Hand Hygiene in Hospital Nurses

Study Overview
=================
Brief Summary
-----------------
Hand hygiene prescriptions are the most important measure in the prevention of hospital acquired infections. Yet compliance rates are generally below 50% of all opportunities for hand hygiene adherence. This study will test the short- and long term effects of two strategies for promoting hand hygiene in hospital nurses

Official Title
-----------------
HELPING HANDS: a Comparison of Short- and Long Term Effects of Alternative Strategies for Promoting Hand Hygiene in Hospital Nurses.

Conditions
-----------------
Handwashing

Intervention / Treatment
-----------------
* Behavioral: state-of-the art strategy and extented strategy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hand hygiene opportunities at the point of patient care Exclusion Criteria: Hand hygiene opportunities not concerning patient care like personal hygiene
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: State of the Art strategy<br>education, reminders, performance feedback, | Behavioral: state-of-the art strategy and extented strategy<br>* state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting<br>|
| Experimental: extended strategy<br>state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting | Behavioral: state-of-the art strategy and extented strategy<br>* state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of adherence of opportunities for hand hygiene |  | march 2008, october 2008, may 2009, november 2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Team climate, Cost effectiveness |  | december 2008, june 2009 |
Study of T3 for the Treatment of Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia. Determine the feasibility and promise of an appropriately powered future prospective randomized controlled study of using T3 (the active form of thyroid hormone) for the treatment of fibromyalgia. We specifically aim to assess the feasibility, cost, obstacles and promise of conducting a prospective controlled study in the future.

Official Title
-----------------
T3 for Fibromyalgia: a Pilot Double-blind Non-randomized Clinical Trial

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Drug: T3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-50 Meet american college of rheumatology criteria for fibromyalgia at baseline report an average pain of 4 or more on a brief Pain Inventory. can climb 2 flights of stairs without shortness of breath. Exclusion Criteria: new medication change in the last 2 months any cardiac disease at all known thyroid disease before or after thyroid screening bloodwork unstable medical or psychiatric disease. Known inflammatory or rheumatic disease other than fibromyalgia substance abuse in the last year suicidality or depression as indicated by a Beck Depression Inventory of 30 or above concomitant herbal medications multiple severe medication allergies the assessment of the research team that inclusion of the subject could in some way compromise the safety and validity of the study. diabetes smoking Known uncontrolled hypertension known uncontrolled hypercholesterolemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Placebo followed by T3<br>Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks. | Drug: T3<br>* Patients receive T3 in a dose of 25mcg and 50mcg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale of Pain Intensity | Patients rated their pain at baseline, placebo, T3 at 25 mcg, and T3 at 50 mcg. The scale ranged from 0 (no pain) to 10 (pain as bad as it can be). | 12 weeks |
Oropharyngeal Dysphagia in Patients With Community Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
This study investigates relationship between community acquired pneumonia and oropharyngeal dysphagia in patients admitted to a department of respiratory medicine in Northern Denmark. The endpoints will be re-hospitalisation and mortality.

Detailed Description
-----------------
Community acquired pneumonia (CAP) is an important cause of morbidity and mortality in elderly patients. Risk factors are many including oropharyngeal dysphagia (OD). Systematic screening of OD is recommended for at-risk popolations, however these resommandations do not specifically address elderly patients hospitalized with CAP. In this study OD is assessed in all patients by Volume-Viscosity Swallowing Test (V-VST) The study is registered by the Danish Data Protection Authority (2008-58-0028)

Official Title
-----------------
Oropharyngeal Dysphagia in Patients With Community Acquired Pneumonia

Conditions
-----------------
Pneumonia, Dysphagia

Intervention / Treatment
-----------------
* Other: Dysphagia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Temperature > 38 degrees Celcius New infiltrate on chest x-ray Increased C-reactive protein (CRP) Either cough, dyspnea, pleuritic chest pain, expectoration, or tachypnea Exclusion Criteria: patients referred from the intensive care unit reduced cognitive awareness if not able to able to cooperate with the assessment of oropharyngeal dysphagia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pneumonia and dysphagia<br>Patients with community aquired pneumonia and oropharyngea dysphagia | Other: Dysphagia<br>* Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test<br>|
| Pneumonia<br>Patients with community aquired pneumonia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intra Hospital Mortality | Intra hospital mortality is death while the patient is hospitalized | With in 10 days from admission | 
| 30 Day Mortality | Death within 30 days of discharge | 30 days after discharge | 
| Re-hospitalization | The rate of re-hospitalization within 30 days of discharge | 30 days after discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dysphagia, Community acquired pneumonia, Mortality, Rehospitalization
Evaluation of Education for Gestational Diabetes

Study Overview
=================
Brief Summary
-----------------
Prospective observational cohort study of women with gestational diabetes (GDM) based on the 'International Association of Pregnancy Study Groups' (IADPSG) criteria. The overall aim is to evaluate the knowledge regarding GDM of women with GDM and to evaluate the satisfaction of women with GDM about the education they receive (given in group or individually). Normal routine care is followed and evaluated.

Official Title
-----------------
Evaluation of Knowledge Regarding Gestational Diabetes and Evaluation of (Group) Education for Gestational Diabetes

Conditions
-----------------
Gestational Diabetes

Intervention / Treatment
-----------------
* Behavioral: education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women ≥ 18 years diagnosed with GDM in the university hospital Leuven. Exclusion Criteria: Women who received bariatric surgery. Women with pregestational diabetes or diagnosed with diabetes during early pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: education|Evaluation of education for GDM|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the knowledge regarding GDM with a self-designed questionnaire |  | over a 2-4 week period | 
| Scale (0 to 3) with questionnaire on depression (CES-D ) |  | over a 2-4 week period | 
| Evaluation of satisfaction with education and Diabetes Treatment Satisfaction Questionnaire |  | over a 2-4 week period | 
| Scale (1-4) with questionnaire on anxiety (six-item short form STAI) |  | over a 2-4 week period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of GDM based on the IADPSG criteria |  | at 24-28 weeks of pregnancy | 
| Composite endpoint of glycaemic control, weight, gestational weight gain and pregnancy outcomes |  | over a period of 16 weeks | 
| The frequency of insulin therapy for GDM |  | over a period of 16 weeks | 
| The time between the glucose challenge test and oral glucose tolerance test |  | at 24-28 weeks of pregnancy | 
| The frequency of an HbA1c ≥6.5% |  | at 24-28 weeks of pregnancy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gestational diabetes, education
CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Thirty-three patients with dry eye (16 Sjögren's syndrome and 17 non-Sjögren's syndrome patients) and 15 control subjects were recruited. The concentrations of CXCL9, CXCL10, and CXCL11 in tears were measured using enzyme-linked immunosorbent assay. The correlation between chemokine levels and tear film and ocular surface parameters was analyzed. Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the conjunctiva was evaluated using immunohistochemistry. Flow cytometry was performed to count CXCR3+ cells and CXCR3+CD4+ cells in the conjunctiva.

Official Title
-----------------
Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the Tear Film and Ocular Surface of Patients With Dry Eye Syndrome

Conditions
-----------------
Dry Eye Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of dry eye syndrome Exclusion Criteria: active ocular infection or inflammation not associated with dry eye drug toxicity contact lens wear ocular allergy ocular surgery within the last 3 months lid or lash abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 77 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal control subjects<br>Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome. | |
| dry eye patients<br>Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dry eye syndrome, CXCL9 chemokine, CXCL10 chemokine, CXCL11 chemokine, CXCR3 receptor
Evaluation of Short-term Outcomes of Ambulatory Loop Ileostomy Reversal

Study Overview
=================
Brief Summary
-----------------
Based on enhanced recovery after surgery (ERAS), ambulatory loop ileostomy reversal (ALIR) has been reported in developed countries. However, there is still no research proposing how to carry out ALIR in developing countries. This study was performed to determine the feasibility of ALIR in China based on the community hospital joined enhanced recovery after surgery (CHJ-ERAS) program.

Detailed Description
-----------------
CHJ-ERAS program for ALIR was launched. Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation. Strict follow-ups were conducted after ALIR. The primary outcome was the results of short-term follow-ups.

Official Title
-----------------
Evaluation of Short-term Outcomes of Ambulatory Loop Ileostomy Reversal

Conditions
-----------------
Fast Recovery Surgery, Surgery

Intervention / Treatment
-----------------
* Other: day-case surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ileostoma and preparing for LIR Patients age between 18-65; ASA grade II; Patients willing to underwent day-case LIR Exclusion Criteria: 1) Patients who underwent single-lumen ileostomy, transverse colostomy or Hartmann; 2) Complex previous laparotomies or required exploratory laparotomy; 3) Age over 65; 4) ASA grade over III (assessed by anesthetists); 5) Presence of moderate or severe preoperative anemia (hemoglobin <90g/L); 6) Therapeutic anticoagulation or anti-platelet medications used within 1 week before surgery; 7) Patient refusal; 8) Severe co-morbidities or other conditions evaluated by surgeons or anesthetists not inappropriate to be included in the program.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| day case group<br>Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation. | Other: day-case surgery<br>* Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Results of short-term follow-up | The occurrence of postoperative complications | Within 1 month after surgery | 
| Readmissions | Readmission within 1 month after surgery | Within 1 month after surgery | 
| Reoperation | Reoperation within 1 month after surgery | Within 1 month after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital stays | Hospital stays | 1 day |